SYFd13707b2ef764c26a3a85ae6e776a4b4Registry ID: 2024-515748-22-01|UnknownPhase 3Results
Loading search results
interventional
N/A
1 country
25
The composite outcome of recurrent MI, all-cause mortality, revascularization with percutaneous coronary intervention or coronary artery bypass graft, ischemic stroke, incident heart failure, malignant ventricular arrhythmia or resuscitated cardiac arrest.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
Not reported
Date not reportedClick on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
August 2, 2024
Actual (reported)The composite outcome of recurrent MI, all-cause mortality, revascularization with percutaneous coronary intervention or coronary atery bypass graft, ischemic stroke, incident heart faliure, malignant ventricular arrythmia or resuscitated cardiac arrest.
Each of the components of the primary endpoint, i.e.: All-cause mortality, recurrent MI, revascularisation with PCI or CABG, ischemic stroke, incident heart failure, malignant ventricular arrhythmia, or resuscitated cardiac arrest.
To assess clinical outcomes linked to beta-blocker therapy in the following subgroups: age, sex, BB dosage tertiles, STEMI vs. NSTEMI, and LVEF subgroups
To study whether oral beta-blocker therapy reduces the risk of cardiovascular death compared to no such therapy
To study whether oral beta-blocker therapy reduces the risk of stable and unstable angina compared to no such therapy
To study whether oral beta-blocker therapy reduces the risk of atrial fibrillation, atrial flutter or other atrial tachyarrhythmias compared to no such therapy
These entries preserve how the registry describes the intervention. Their treatment roles are shown separately from molecular identities.
Formulated product
Carvedilol STADA 3,125 mg töflur.
The registry describes a specific formulation. Its exact chemical ingredients and approval status require separate evidence.
TABLET
View registry recordFormulated product
Metoprololsuccinat "Polpharma", depottabletter
The registry describes a specific formulation. Its exact chemical ingredients and approval status require separate evidence.
PROLONGED-RELEASE TABLET
View registry recordFormulated product
Metoprololsuccinat "Polpharma", depottabletter
The registry describes a specific formulation. Its exact chemical ingredients and approval status require separate evidence.
PROLONGED-RELEASE TABLET
View registry recordFormulated product
Carvedilol STADA 6,25 mg töflur.
The registry describes a specific formulation. Its exact chemical ingredients and approval status require separate evidence.
TABLET
View registry recordFormulated product
Carvedilol STADA 12,5 mg tabletti
The registry names these ingredients. The formulation’s exact chemical form has not been confirmed.
Carvedilol STADA 3,125 mg töflur.
Named ingredient: Carvedilol
View registry recordMetoprololsuccinat "Polpharma", depottabletter
Named ingredient: Metoprolol tartrate
View registry recordMetoprololsuccinat "Polpharma", depottabletter
Named ingredient: Metoprolol tartrate
View registry recordCarvedilol STADA 6,25 mg töflur.
Named ingredient: Carvedilol
View registry recordCarvedilol STADA 12,5 mg tabletti
Named ingredient: Carvedilol
View registry recordCarvedilol STADA 6,25 mg tabletti
Named ingredient: Carvedilol
View registry recordCarvedilol STADA 3,125 mg tabletti
Named ingredient: Carvedilol
Lillebaelt Hospital
Kolding, 6000, Denmark
Sygehus Soenderjylland Soenderborg
Aabenraa, 6200, Denmark
Amager Hospital
Copenhagen S, 2300, Denmark
Eva Prescott
First Submitted
August 2, 2024
Download the complete CTIS (EMA) record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: European Medicines Agency (EMA), Clinical Trials Information System (CTIS). Original record and public documents are available on CTIS.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved:
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
The registry describes a specific formulation. Its exact chemical ingredients and approval status require separate evidence.
TABLET
Formulated product
Carvedilol STADA 6,25 mg tabletti
The registry describes a specific formulation. Its exact chemical ingredients and approval status require separate evidence.
TABLET
View registry recordFormulated product
Carvedilol STADA 3,125 mg tabletti
The registry describes a specific formulation. Its exact chemical ingredients and approval status require separate evidence.
TABLET
View registry recordFormulated product
Carvedilol STADA® 6,25 mg Tabletten
The registry describes a specific formulation. Its exact chemical ingredients and approval status require separate evidence.
TABLET
View registry recordFormulated product
Carvedilol STADA 25 mg tabletti
The registry describes a specific formulation. Its exact chemical ingredients and approval status require separate evidence.
TABLET
View registry recordFormulated product
Carvedilol STADA® 25 mg Tabletten
The registry describes a specific formulation. Its exact chemical ingredients and approval status require separate evidence.
TABLET
View registry recordFormulated product
Carvedilol STADA 12,5 mg töflur
The registry describes a specific formulation. Its exact chemical ingredients and approval status require separate evidence.
TABLET
View registry recordFormulated product
Carvedilol STADA 25 mg Tabletten
The registry describes a specific formulation. Its exact chemical ingredients and approval status require separate evidence.
TABLET
View registry recordFormulated product
Carvedilol STADA 12,5 mg Tabletten
The registry describes a specific formulation. Its exact chemical ingredients and approval status require separate evidence.
TABLET
View registry recordFormulated product
Metoprololsuccinat "Polpharma", depottabletter
The registry describes a specific formulation. Its exact chemical ingredients and approval status require separate evidence.
PROLONGED-RELEASE TABLET
View registry recordFormulated product
Metoprololsuccinat "Polpharma", depottabletter
The registry describes a specific formulation. Its exact chemical ingredients and approval status require separate evidence.
PROLONGED-RELEASE TABLET
View registry recordFormulated product
Carvedilol STADA 25 mg töflur.
The registry describes a specific formulation. Its exact chemical ingredients and approval status require separate evidence.
TABLET
View registry recordFormulated product
Carvedilol STADA 6,25 mg Tabletten
The registry describes a specific formulation. Its exact chemical ingredients and approval status require separate evidence.
TABLET
View registry recordFormulated product
Carvedilol STADA® 12,5 mg Tabletten
The registry describes a specific formulation. Its exact chemical ingredients and approval status require separate evidence.
TABLET
View registry recordCarvedilol STADA® 6,25 mg Tabletten
Named ingredient: Carvedilol
View registry recordCarvedilol STADA 25 mg tabletti
Named ingredient: Carvedilol
View registry recordCarvedilol STADA® 25 mg Tabletten
Named ingredient: Carvedilol
View registry recordCarvedilol STADA 12,5 mg töflur
Named ingredient: Carvedilol
View registry recordCarvedilol STADA 25 mg Tabletten
Named ingredient: Carvedilol
View registry recordCarvedilol STADA 12,5 mg Tabletten
Named ingredient: Carvedilol
View registry recordMetoprololsuccinat "Polpharma", depottabletter
Named ingredient: Metoprolol tartrate
View registry recordMetoprololsuccinat "Polpharma", depottabletter
Named ingredient: Metoprolol tartrate
View registry recordCarvedilol STADA 25 mg töflur.
Named ingredient: Carvedilol
View registry recordCarvedilol STADA 6,25 mg Tabletten
Named ingredient: Carvedilol
View registry recordCarvedilol STADA® 12,5 mg Tabletten
Named ingredient: Carvedilol
View registry recordContact the study team to confirm eligibility.
Region Midtjylland
Horsens, 8700, Denmark
Rigshospitalet
Glostrup, 2600, Denmark
Copenhagen University Hospital
Roskilde, 4000, Denmark
Aalborg University Hospital
Aalborg, 9000, Denmark
Rigshospitalet
Roenne, 3700, Denmark
Nordsjaellands Hospital
Hilleroed, 3400, Denmark
Region Midtjylland
Viborg, 8800, Denmark
Odense University Hospital
Svendborg, 5700, Denmark
Gentofte Hospital
Hellerup, 2900, Denmark
Hvidovre Hospital
Hvidovre, 2650, Denmark
Slagelse Hospital
Slagelse, 4200, Denmark
Copenhagen University Hospital
Herlev, 2730, Denmark
Copenhagen University Hospital
Copenhagen Nv, 2400, Denmark
Holbaek Sygehus
Holbæk, 4300, Denmark
Copenhagen University Hospital
Roskilde, 4000, Denmark
Sygehus Lillebaelt Vejle Sygehus
Vejle, 7100, Denmark
Region Midtjylland
Herning, 7400, Denmark
Esbjerg Og Grindsted Sygehus
Esbjerg, 6700, Denmark
Odense University Hospital
Odense C, 5000, Denmark
Aarhus Universitetshospital
Aarhus N, 8200, Denmark
Regionshospital Nordjylland
Hjoerring, 9800, Denmark
Næstved Hospital
Næstved, 4700, Denmark